In this issue:
Erlotinib retreatment in NSCLC initially responsive to EGFR-TKI
Histology as predictor of RT response in NSCLC
Thoracic RT and survival in extensive-stage SCLC
Biomarkers of erlotinib efficacy in advanced NSCLC
CXR screening and lung cancer mortality
Please login below to download this issue (PDF)